Precision Oncology Is Moving Beyond One Gene and One Drug

One gene, one drug was always a shorthand

The story is easy to tell. Find the broken gene. Give the drug that blocks it. Watch the tumor shrink.

That story is true for a handful of situations. NCI gives the clearest example: cancers with certain changes in the EGFR gene can be treated with drugs that target those changes. Clean input, clean output.

Most cases are messier. A tumor can carry several changes at once. Some changes have no matching drug. Some drugs work in one cancer type and fail in another with the same change.

What a match actually requires

NCI describes precision medicine as care shaped by the genes, proteins, and other substances in your body. In cancer treatment, that means using tests to pick treatments more likely to help and to skip ones unlikely to.

The test that opens that door is biomarker testing. NCI also calls it tumor testing, genomic profiling, or molecular profiling. It looks at the cancer, not at genes you inherited.

Some tests are locked to one drug. NCI calls those companion diagnostic tests. Without the matching result, the drug is not prescribed.

What NCI-MATCH found

NCI-MATCH is the largest US trial built on this idea. Its design was simple to state. Sequence the tumor. Assign treatment by the genetic change, whatever the cancer type.

The numbers NCI reports:

• 1,201 people enrolled.
• 38 different treatment arms.
• Roughly 60 percent had cancers other than colon, rectal, breast, non-small cell lung, or prostate.
• Drugs used were either FDA-approved for a different cancer or still in testing.

NCI's summary of the result is measured. It says the trial showed that people with advanced cancer may benefit from genomic sequencing to help plan their treatment. "May benefit" is doing real work in that sentence. It is not a claim that sequencing helps everyone.

What came next tells you what was missing

NCI-MATCH has stopped enrolling. Its successors are built around what it could not do. ComboMATCH tests drug combinations instead of single drugs. MyeloMATCH covers acute myeloid leukemia and myelodysplastic syndromes, which NCI-MATCH excluded. ImmunoMATCH looks at the immune state of a tumor.

Each of those is an admission. One gene and one drug was not enough.

Beyond the gene list

Newer work adds layers. Protein levels. Immune cells inside the tumor. Patterns in scans. Details from the pathology report, such as grade and how far the cancer has spread.

Your pathology report already holds several of these. It is not a genomic test, and it still shapes treatment.

More data is not automatically better. Each added layer brings its own error rate. Combining noisy inputs can produce a confident-looking answer that is wrong.

The failure mode nobody advertises

The honest outcome of a full tumor profile is often this: a change was found, and no treatment matches it. Or a change was found, and the matching drug is only available in a trial that is not enrolling near you.

That is not a wasted test. It rules things out. But a person who was told the test would find an answer can feel it as a second diagnosis.

Ask before testing what happens if nothing actionable turns up.

Before the test is ordered

• What exactly does this test cover, and what does it miss?
• How long until results come back?
• If a change is found, is there an approved targeted treatment or only a trial?
• Was the sample taken from the original tumor or a newer site?
• Will insurance cover the test and the drug?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.